Cannabis research flourishes across the globe, with over 4,300 scientific research studies published in 2022.
Hundreds more studies were published on cannabis in 2022 than in previous years, according to figures collected by NORML.
Since 2010, over 30,000 scientific papers specific to cannabis have been published according to NORML. However, this is the highest number of cannabis-specific papers ever published in a single year.
The majority of recent papers have focused on the therapeutic potential of the plant. One area of research that has seen particularly significant growth is the use of cannabis for the treatment of chronic pain. Many studies have shown that it can be an effective alternative to traditional pain management methods such as opioids which can be highly addictive.
Other areas of research include the use of cannabis for the treatment of mental health conditions such as anxiety and depression, as well as its potential as an anti-inflammatory agent. In addition, there are several ongoing studies and clinical trials into the use of cannabis to treat epilepsy and other neurological disorders.
While the results of these studies have been promising, it is important to note that there is still much that needs to be done to improve accessibility and understanding for existing patients and prospective patients here in the UK and across Europe. This includes increasing the number of prescribers and making prescriptions more affordable.
As more evidence from clinical trials starts to emerge and real-world data is gathered from patient feedback, this will play a huge role in addressing the many challenges that the medical cannabis industry currently faces. We will be following the latest legislation updates very closely, along with the very latest patient case studies, so make sure you are following us on social media to stay up to date with the latest news.
We think you might also like this posts:
At Ecoinomy, we believe that good health is a global fundamental right and that every human being deserves access to affordable, accessible healthcare. As we approach Earth Day 2023, we’re showcasing how good human health and planetary health are intrinsically
An MHRA license is required to manufacture Cannabis-based products for medicinal use (CBPMs) and active pharmaceutical ingredients (API). This license requires an inspection of the site to confirm it has an appropriate facility, staff and Pharmaceutical Quality Management System and has carried out the required activities (including process and analytical validation). There currently isn’t a way to operate both authorisation processes independently because each regulatory authorisation process requires some aspects of the other. Which presents a problem for new companies looking to enter the market. … Read More